Covid-19 Updates & Info
- ponchi101
- Site Admin
- Posts: 16460
- Joined: Mon Dec 07, 2020 4:40 pm
- Location: New Macondo
- Has thanked: 4173 times
- Been thanked: 6470 times
- Contact:
Re: Covid-19 Updates & Info
A very respected person here in the country. Worked for almost every government since he came into public life.
Ego figere omnia et scio supellectilem
- Suliso
- Posts: 4771
- Joined: Fri Dec 11, 2020 2:30 pm
- Location: Basel, Switzerland
- Has thanked: 291 times
- Been thanked: 1608 times
Re: Covid-19 Updates & Info
I used to post some covid statistics on TAT 1.0. Not as extensive this time, only the final mortality rate. Top 10 plus some notables excluding micro states. Note that 1000 means that 0.1% of the countries population has died from the disease in the last year or so.
Deaths per 1 million inhabitants
Belgium 1,791
Slovenia 1,638
UK 1,471
Czechia 1,457
Italy 1,431
Bosnia and Herzegovina 1,414
North Macedonia 1,350
USA 1,309
Bulgaria 1,284
Hungary 1,256
-------
Spain 1,215
Peru 1,200 (worst in SA)
Mexico 1,159
France 1,134
Sweden 1,110
Portugal 1,082 (currently the worst outbreak in EU)
Switzerland 1,059
Argentina 1,040
Brazil 1,026 (I suspect undercounting)
Colombia 1,018
Germany 648
Ireland 617
Latvia 601
Canada 511
Israel 491 (current leader in vaccinations)
Denmark 350
Finland 118
Norway 101 (best in continental Europe)
Deaths per 1 million inhabitants
Belgium 1,791
Slovenia 1,638
UK 1,471
Czechia 1,457
Italy 1,431
Bosnia and Herzegovina 1,414
North Macedonia 1,350
USA 1,309
Bulgaria 1,284
Hungary 1,256
-------
Spain 1,215
Peru 1,200 (worst in SA)
Mexico 1,159
France 1,134
Sweden 1,110
Portugal 1,082 (currently the worst outbreak in EU)
Switzerland 1,059
Argentina 1,040
Brazil 1,026 (I suspect undercounting)
Colombia 1,018
Germany 648
Ireland 617
Latvia 601
Canada 511
Israel 491 (current leader in vaccinations)
Denmark 350
Finland 118
Norway 101 (best in continental Europe)
- Deuce
- Posts: 4531
- Joined: Wed Dec 09, 2020 5:52 am
- Location: An unparallel universe
- Has thanked: 313 times
- Been thanked: 955 times
Re: Covid-19 Updates & Info
Just to add further context...Suliso wrote: ↑Tue Jan 26, 2021 11:07 pm I used to post some covid statistics on TAT 1.0. Not as extensive this time, only the final mortality rate. Top 10 plus some notables excluding micro states. Note that 1000 means that 0.1% of the countries population has died from the disease in the last year or so.
Deaths per 1 million inhabitants
Belgium 1,791
Slovenia 1,638
UK 1,471
Czechia 1,457
Italy 1,431
Bosnia and Herzegovina 1,414
North Macedonia 1,350
USA 1,309
Bulgaria 1,284
Hungary 1,256
-------
Spain 1,215
Peru 1,200 (worst in SA)
Mexico 1,159
France 1,134
Sweden 1,110
Portugal 1,082 (currently the worst outbreak in EU)
Switzerland 1,059
Argentina 1,040
Brazil 1,026 (I suspect undercounting)
Colombia 1,018
Germany 648
Ireland 617
Latvia 601
Canada 511
Israel 491 (current leader in vaccinations)
Denmark 350
Finland 118
Norway 101 (best in continental Europe)
Australia - deaths per 1 Million inhabitants: 36.
Australia is a 'modern' country with large cities. If they can handle the virus this well, why can't other modern countries with big cities?
They could have, had they taken the same approach as Australia has.
(Of course, Australia may go all to hell now that they've allowed the infected tennis population in...)
R.I.P. Amal...
“The opposite of courage is not cowardice - it’s conformity. Even a dead fish can go with the flow.”- Jim Hightower
“The opposite of courage is not cowardice - it’s conformity. Even a dead fish can go with the flow.”- Jim Hightower
- Suliso
- Posts: 4771
- Joined: Fri Dec 11, 2020 2:30 pm
- Location: Basel, Switzerland
- Has thanked: 291 times
- Been thanked: 1608 times
Re: Covid-19 Updates & Info
Do special advantages of Australia and New Zealand really need to be spelled out? We're all smart enough to understand...
- JazzNU
- Posts: 6655
- Joined: Sun Jan 03, 2021 6:57 pm
- Location: Pennsylvania
- Has thanked: 2740 times
- Been thanked: 2314 times
Re: Covid-19 Updates & Info
For the previous convo on vaccine by manufacturer, I was on the CDC website today looking at the numbers for different states and the current breakdown nationwide is:
13 million Pfizer
10.4 million Moderna
13 million Pfizer
10.4 million Moderna
- dryrunguy
- Posts: 1622
- Joined: Thu Dec 10, 2020 6:31 am
- Has thanked: 724 times
- Been thanked: 1195 times
Re: Covid-19 Updates & Info
The latest Situation Report.
::
...
ECONOMIC IMPACT & RECOVERY A report published this week by Oxfam International illustrates significant disparities in terms of the financial impact of the COVID-19 pandemic. The report—released to coincide with the annual World Economic Forum summit typically held in Davos, Switzerland—indicates that the “mega-rich” have already recovered financially from the pandemic, whereas the world’s poorest could take years or longer. Notably, the research suggests that COVID-19 could exacerbate economic inequalities in nearly every country on Earth. The 1,000 wealthiest people in the world, “mostly White male,” took approximately 9 months to recuperate financial losses, but those living in poverty are expected to take more than a decade to recover. The analysis also estimates that “the increase in the 10 richest billionaires’ wealth since the crisis began [more than US$500 billion] is more than enough to prevent anyone on Earth from falling into poverty because of the virus, and to pay for a COVID-19 vaccine for everyone.” Notably, women and racial and ethnic minorities are disproportionately affected by the global economic crisis. In addition to shorter-term and immediate financial struggles, many people around the world will face prolonged financial hardship stemming from the pandemic, compounding economic inequalities around the world.
https://covid19.who.int/
Dry.
I AM SORRY. I thought I was replying to your post, and I clicked the EDIT button instead. I deleted your post.
I am super sorry. I am still sometimes lost here.
Can you re-post, please?
::
...
ECONOMIC IMPACT & RECOVERY A report published this week by Oxfam International illustrates significant disparities in terms of the financial impact of the COVID-19 pandemic. The report—released to coincide with the annual World Economic Forum summit typically held in Davos, Switzerland—indicates that the “mega-rich” have already recovered financially from the pandemic, whereas the world’s poorest could take years or longer. Notably, the research suggests that COVID-19 could exacerbate economic inequalities in nearly every country on Earth. The 1,000 wealthiest people in the world, “mostly White male,” took approximately 9 months to recuperate financial losses, but those living in poverty are expected to take more than a decade to recover. The analysis also estimates that “the increase in the 10 richest billionaires’ wealth since the crisis began [more than US$500 billion] is more than enough to prevent anyone on Earth from falling into poverty because of the virus, and to pay for a COVID-19 vaccine for everyone.” Notably, women and racial and ethnic minorities are disproportionately affected by the global economic crisis. In addition to shorter-term and immediate financial struggles, many people around the world will face prolonged financial hardship stemming from the pandemic, compounding economic inequalities around the world.
https://covid19.who.int/
Dry.
I AM SORRY. I thought I was replying to your post, and I clicked the EDIT button instead. I deleted your post.
I am super sorry. I am still sometimes lost here.
Can you re-post, please?
- ponchi101
- Site Admin
- Posts: 16460
- Joined: Mon Dec 07, 2020 4:40 pm
- Location: New Macondo
- Has thanked: 4173 times
- Been thanked: 6470 times
- Contact:
Re: Covid-19 Updates & Info
About AUS and NZ. I said it: wealthy island nations that could isolate quickly, with low population densities, and separated from every body else. Plus, populations that could count on some social security network and not be forced to go out, having to choose between the chance of catching the virus or the certainty of going hungry.
Ego figere omnia et scio supellectilem
- dryrunguy
- Posts: 1622
- Joined: Thu Dec 10, 2020 6:31 am
- Has thanked: 724 times
- Been thanked: 1195 times
Re: Covid-19 Updates & Info
Here's the most recent Situation Report.
::
EPI UPDATE The WHO COVID-19 Dashboard reports 99.36 million cases and 2.14 million deaths as of 11am EST on January 26. The WHO reported decreasing global incidence for the second consecutive week, down to 4.10 million new cases last week, a 15.2% decrease from the previous week. But even with the recent decline, the average global daily incidence exceeds 575,000 new cases per day. At this pace, we expect the global cumulative incidence to surpass 100 million cases in the next 2 days. While daily incidence is decreasing, mortality continues to increase. The WHO reported 95,991 deaths last week, a new record and an increase of slightly more than 1% compared to the previous week.
Our World in Data reports that 55.58 million vaccine doses have been administered globally.
UNITED STATES
The US CDC reported 25.02 million total cases and 417,936 deaths. The US surpassed 25 million cumulative cases in yesterday’s update.
1 case to 5 million cases- 200 days
5 million to 10 million- 92 days
10 million to 15 million- 29 days
15 million to 20 million- 24 days
20 million to 25 million- 23 days
It is becoming more clear that the US has passed a peak in terms of daily incidence, and the current average is less than what it was prior to the Thanksgiving holiday weekend. In light of fluctuations in reporting over the winter holidays, it is difficult to determine when the daily incidence actually peaked; however, the peak in terms of reported incidence was 248,706 new cases per day on January 8. In addition to daily incidence, we are beginning to observe an associated decrease in hospitalizations at the national level.
This trend is evident at the regional and state levels as well. All 4 regions have reported decreasing daily incidence since approximately January 8-10, including a further decrease in the Midwest, which has reported a steady decline in daily incidence since mid-to-late November. According to data from the COVID Exit Strategy website, 28 states are reporting decreasing daily incidence over the past 2 weeks, including nearly every state stretching from the Midwest to the Pacific Northwest as well as several states in the South, Mid-Atlantic, and Northeast. According to data from The COVID Tracking Project, 45 states (plus Washington, DC) are reporting decreasing daily incidence over the past week, and 5 are holding steady (-10% to +10%). In fact, only Tennessee is reporting increased incidence over the past week, but at +7%, it still falls under the category of “Staying the Same.” Similarly, hospitalizations are decreasing in all 4 regions. Additionally, 33 states are reporting decreasing hospitalizations over the past week, and 15 (plus Washington, DC) are reporting steady hospitalizations (-10% to +10%)—compared to only 2 states reporting increases.
Looking at mortality at the regional level, COVID-19 deaths continue to decrease steadily in the Midwest, and the Northeast region appears to have recently passed a peak. The South and West regions may be at or approaching their own peaks, but holiday-related delays in reporting make it difficult to determine the longer-term trend in these regions. At the state level, 21 states (plus Washington, DC) are reporting decreasing daily mortality over the past week, compared to 11 with increasing mortality and 18 holding relatively steady (-10% to +10%).
The US has now administered more than half of the distributed vaccine doses. The US CDC reported 41.42 million vaccine doses distributed and 22.73 million doses administered (54.9%%), including 2.71 million administered in long-term care facilities (LTCFs). In total, 19.25 million people have received at least 1 dose of the vaccine, and 3.35 million have received both doses. The US is now averaging 1.13 million doses administered per day, an increase of 35% compared to this time last week. The breakdown of doses by manufacturer remains relatively even, with slightly more Pfizer/BioNTech doses administered (12.55 million; 55%) than Moderna (10.08 million; 45%).
The Johns Hopkins CSSE dashboard reported 25.34 million US cases and 422,583 deaths as of 1:30pm EST on January 26.
EMERGING VARIANTS & MORTALITY New evidence indicates the B.1.1.7 variant of concern (VOC) may be associated with increased mortality compared to other strains of SARS-CoV-2. At a press conference this week, Sir Patrick Vallance, the UK’s Government Chief Scientific Advisor, said that infection with the new variant may be associated with an increased risk of death, in addition to its increased transmissibility. He noted that the mortality risk could be on the order of 30-40% higher for some individuals, but he also said that further analysis is needed to better characterize this relationship. Analysis published by the UK’s New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) found that that mortality risk was significantly higher in individuals infected with the B.1.1.7 variant across multiple age groups, with increases ranging from 29% to 91% in multiple studies.
In response to the potential for increased mortality, UK Prime Minister Boris Johnson called for redoubled vigilance and adherence to COVID-19 prevention measures in order to protect the capacity of national healthcare system. Fortunately, current vaccine candidates still appear to be effective against the variant. The UK government will continue to drive toward its goal of vaccinating 15 million people by mid-February in order to protect the most vulnerable against infection by any variant of SARS-CoV-2.
In the US, Dr. Anthony Fauci acknowledged the NERVTAG results as highly concerning and in need of further study in the coming weeks. He emphasized that current vaccines still appear to be effective against existing VOCs, but adjustments can and will be made as needed. Dr. Fauci did note that monoclonal antibody treatments did appear to be significantly less effective against some VOCs compared to reference strains.
VACCINE DEVELOPMENT & EFFICACY On January 25, Merck announced that it “is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates” as a result of poor performance during Phase 1 clinical trials. While Merck’s 2 candidates were well tolerated from a safety perspective, the immune response generated in the study participants was “inferior to those seen following natural infection and...for other SARS-CoV-2/COVID-19 vaccines.” The Merck vaccines were highly anticipated, as they used viral platforms that could replicate in the human body, which had the potential to confer longer-lasting immunity with a single dose.
Despite having already received authorization for the use of its SARS-CoV-2 vaccine in multiple countries, Moderna is already developing a booster to better protect against emerging variants. On January 25, Moderna announced preliminary results from a study assessing the current vaccine’s efficacy against emerging variants, including B.1.1.7 and B.1.351. Compared to reference strains, the vaccine did not exhibit any decrease in neutralizing antibody titers against the B.1.1.7 variant. Conversely, the vaccine exhibited a 6-fold reduction in neutralizing antibodies effective against the B.1.351 variant, which could indicate a lesser degree of protection or faster waning of immunity. A press release from the company indicated that while the immune response was lower, the vaccine did offer some protection. Considering that the immune response from the vaccine appears to be stronger than from natural infection, a moderate decrease in efficacy could still provide a meaningful degree of protection. In response to the concerning results, Moderna announced that it is in the process of developing a new booster that is tailored to provide increased protection against the B.1.351 variant. Additionally, Moderna is testing the effect of a second booster dose of the existing vaccine to determine any additional benefit in terms of protection against the B.1.351 variant. Considering that Moderna’s existing vaccine is already authorized for use in multiple countries, it is unclear what the regulatory review process would look like for a new booster or an additional booster dose.
AUSTRALIA VACCINE AUTHORIZATION On January 25, the Australian Therapeutic Goods Administration granted provisional authorization for the use of the Pfizer/BioNTech vaccine candidate. The provisional approval applies for use in individuals aged 16 years and older, and vaccinations are expected to begin in February. Australian Prime Minister Scott Morrison emphasized that the provisional approval is different from an emergency authorization and requires a more comprehensive review of the vaccine’s safety and efficacy, among the first such effort globally. The vaccine will be provided for free to all Australian citizens. According to the National Rollout Strategy, as many as 1.4 million doses will be distributed to “1a” priority groups, which include healthcare workers, long-term care facility staff and residents, and border and quarantine workers. The vaccine will initially be delivered to 50 priority vaccination sites during Phase 1a and then expanded to more than 1,000 sites nationwide. The initial vaccine hubs are concentrated in coastal areas, where the majority of the population resides. Few of the initial sites are located in Australia’s interior where many aboriginal communities reside. Australian authorities must set up cold storage facilities and train vaccinators in advance of beginning Phase 1a, and each batch will be tested before doses are administered.
VACCINE DONATIONS India has pledged to donate more than 4.5 million doses of the AstraZeneca vaccine, manufactured in India by the Serum Institute, to several neighboring countries. Deliveries have reportedly already arrived in Bangladesh, Bhutan, Maldives, Mauritius, Nepal, and Seychelles, and additional donations are expected for Afghanistan and Sri Lanka. India has already stockpiled 80 million doses of the AstraZeneca vaccine, and it is expected to manufacture an additional 50 million doses per month. In addition to India, China has donated vaccine to numerous countries, including Myanmar, Cambodia, Philippines, and Pakistan. Commentators have noted that these donations may be a strategic form of diplomacy that aims, in part, to increase political influence in the region and improve bilateral relations. In addition to donations, both India and China have also sold doses of vaccine to global partners.
US TRAVEL RESTRICTIONS Yesterday, US President Joe Biden issued travel restrictions for several countries that are currently experiencing increased COVID-19 incidence, including several emerging variants of SARS-CoV-2. The restrictions apply to individuals who traveled to Brazil, Ireland, South Africa, the UK, or any country in the EU (Schengen Area) in the 14 days prior to their arrival in the US. The restrictions existed previously for Brazil, Ireland, the UK, and the EU, but South Africa is new to the list. The presidential proclamation took effect today. Dr. Anthony Fauci described the restrictions as “very prudent,” particularly as new evidence indicates that these emerging variants may be associated with increased mortality risk. Exceptions to the new policy include US citizens, permanent residents, noncitizen nationals, certain immediate family members of permanent residents or citizens, individuals who fall under exceptions related to US national interests and individuals seeking asylum.
MEXICAN PRESIDENT On Sunday, Mexican President Andrés Manuel López Obrador announced that he tested positive for SARS-CoV-2. President Obrador described his symptoms as “mild,” but he is currently undergoing medical treatment. President Obrador will continue to isolate at home, and he has handed off responsibility for daily news conferences to Mexico’s Secretary of the Interior, Olga Sánchez Cordero. President Obrador had not yet been vaccinated against SARS-CoV-2.
RESTRICTIONS & PROTESTS For the past several days in the Netherlands, protests against stronger COVID-19 restrictions have turned violent. The Dutch government implemented new ”lockdown measures” on January 23, including a nighttime curfew from 8:30pm-4:30am, a travel advisory discouraging any travel out of the country, and a limit of 1 visitor per household per day. The curfew, in particular, drew opposition from the public. As we covered previously, the last time that the Netherlands implemented a nationwide curfew was during World War II. The large public protests turned violent on Sunday the 24, reportedly including a fire at a SARS-CoV-2 testing center. Since then, hundreds of protestors have been arrested, and several cities have imposed ordinances against entering the city center in order to suppress further riots. Prime Minister Mark Rutte condemned the riots, describing the events as instances of criminal violence rather than protests. The curfew and other new measures are scheduled to remain in place through February 9.
ECONOMIC IMPACT & RECOVERY A report published this week by Oxfam International illustrates significant disparities in terms of the financial impact of the COVID-19 pandemic. The report—released to coincide with the annual World Economic Forum summit typically held in Davos, Switzerland—indicates that the “mega-rich” have already recovered financially from the pandemic, whereas the world’s poorest could take years or longer. Notably, the research suggests that COVID-19 could exacerbate economic inequalities in nearly every country on Earth. The 1,000 wealthiest people in the world, “mostly White male,” took approximately 9 months to recuperate financial losses, but those living in poverty are expected to take more than a decade to recover. The analysis also estimates that “the increase in the 10 richest billionaires’ wealth since the crisis began [more than US$500 billion] is more than enough to prevent anyone on Earth from falling into poverty because of the virus, and to pay for a COVID-19 vaccine for everyone.” Notably, women and racial and ethnic minorities are disproportionately affected by the global economic crisis. In addition to shorter-term and immediate financial struggles, many people around the world will face prolonged financial hardship stemming from the pandemic, compounding economic inequalities around the world.
https://covid19.who.int/
::
EPI UPDATE The WHO COVID-19 Dashboard reports 99.36 million cases and 2.14 million deaths as of 11am EST on January 26. The WHO reported decreasing global incidence for the second consecutive week, down to 4.10 million new cases last week, a 15.2% decrease from the previous week. But even with the recent decline, the average global daily incidence exceeds 575,000 new cases per day. At this pace, we expect the global cumulative incidence to surpass 100 million cases in the next 2 days. While daily incidence is decreasing, mortality continues to increase. The WHO reported 95,991 deaths last week, a new record and an increase of slightly more than 1% compared to the previous week.
Our World in Data reports that 55.58 million vaccine doses have been administered globally.
UNITED STATES
The US CDC reported 25.02 million total cases and 417,936 deaths. The US surpassed 25 million cumulative cases in yesterday’s update.
1 case to 5 million cases- 200 days
5 million to 10 million- 92 days
10 million to 15 million- 29 days
15 million to 20 million- 24 days
20 million to 25 million- 23 days
It is becoming more clear that the US has passed a peak in terms of daily incidence, and the current average is less than what it was prior to the Thanksgiving holiday weekend. In light of fluctuations in reporting over the winter holidays, it is difficult to determine when the daily incidence actually peaked; however, the peak in terms of reported incidence was 248,706 new cases per day on January 8. In addition to daily incidence, we are beginning to observe an associated decrease in hospitalizations at the national level.
This trend is evident at the regional and state levels as well. All 4 regions have reported decreasing daily incidence since approximately January 8-10, including a further decrease in the Midwest, which has reported a steady decline in daily incidence since mid-to-late November. According to data from the COVID Exit Strategy website, 28 states are reporting decreasing daily incidence over the past 2 weeks, including nearly every state stretching from the Midwest to the Pacific Northwest as well as several states in the South, Mid-Atlantic, and Northeast. According to data from The COVID Tracking Project, 45 states (plus Washington, DC) are reporting decreasing daily incidence over the past week, and 5 are holding steady (-10% to +10%). In fact, only Tennessee is reporting increased incidence over the past week, but at +7%, it still falls under the category of “Staying the Same.” Similarly, hospitalizations are decreasing in all 4 regions. Additionally, 33 states are reporting decreasing hospitalizations over the past week, and 15 (plus Washington, DC) are reporting steady hospitalizations (-10% to +10%)—compared to only 2 states reporting increases.
Looking at mortality at the regional level, COVID-19 deaths continue to decrease steadily in the Midwest, and the Northeast region appears to have recently passed a peak. The South and West regions may be at or approaching their own peaks, but holiday-related delays in reporting make it difficult to determine the longer-term trend in these regions. At the state level, 21 states (plus Washington, DC) are reporting decreasing daily mortality over the past week, compared to 11 with increasing mortality and 18 holding relatively steady (-10% to +10%).
The US has now administered more than half of the distributed vaccine doses. The US CDC reported 41.42 million vaccine doses distributed and 22.73 million doses administered (54.9%%), including 2.71 million administered in long-term care facilities (LTCFs). In total, 19.25 million people have received at least 1 dose of the vaccine, and 3.35 million have received both doses. The US is now averaging 1.13 million doses administered per day, an increase of 35% compared to this time last week. The breakdown of doses by manufacturer remains relatively even, with slightly more Pfizer/BioNTech doses administered (12.55 million; 55%) than Moderna (10.08 million; 45%).
The Johns Hopkins CSSE dashboard reported 25.34 million US cases and 422,583 deaths as of 1:30pm EST on January 26.
EMERGING VARIANTS & MORTALITY New evidence indicates the B.1.1.7 variant of concern (VOC) may be associated with increased mortality compared to other strains of SARS-CoV-2. At a press conference this week, Sir Patrick Vallance, the UK’s Government Chief Scientific Advisor, said that infection with the new variant may be associated with an increased risk of death, in addition to its increased transmissibility. He noted that the mortality risk could be on the order of 30-40% higher for some individuals, but he also said that further analysis is needed to better characterize this relationship. Analysis published by the UK’s New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) found that that mortality risk was significantly higher in individuals infected with the B.1.1.7 variant across multiple age groups, with increases ranging from 29% to 91% in multiple studies.
In response to the potential for increased mortality, UK Prime Minister Boris Johnson called for redoubled vigilance and adherence to COVID-19 prevention measures in order to protect the capacity of national healthcare system. Fortunately, current vaccine candidates still appear to be effective against the variant. The UK government will continue to drive toward its goal of vaccinating 15 million people by mid-February in order to protect the most vulnerable against infection by any variant of SARS-CoV-2.
In the US, Dr. Anthony Fauci acknowledged the NERVTAG results as highly concerning and in need of further study in the coming weeks. He emphasized that current vaccines still appear to be effective against existing VOCs, but adjustments can and will be made as needed. Dr. Fauci did note that monoclonal antibody treatments did appear to be significantly less effective against some VOCs compared to reference strains.
VACCINE DEVELOPMENT & EFFICACY On January 25, Merck announced that it “is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates” as a result of poor performance during Phase 1 clinical trials. While Merck’s 2 candidates were well tolerated from a safety perspective, the immune response generated in the study participants was “inferior to those seen following natural infection and...for other SARS-CoV-2/COVID-19 vaccines.” The Merck vaccines were highly anticipated, as they used viral platforms that could replicate in the human body, which had the potential to confer longer-lasting immunity with a single dose.
Despite having already received authorization for the use of its SARS-CoV-2 vaccine in multiple countries, Moderna is already developing a booster to better protect against emerging variants. On January 25, Moderna announced preliminary results from a study assessing the current vaccine’s efficacy against emerging variants, including B.1.1.7 and B.1.351. Compared to reference strains, the vaccine did not exhibit any decrease in neutralizing antibody titers against the B.1.1.7 variant. Conversely, the vaccine exhibited a 6-fold reduction in neutralizing antibodies effective against the B.1.351 variant, which could indicate a lesser degree of protection or faster waning of immunity. A press release from the company indicated that while the immune response was lower, the vaccine did offer some protection. Considering that the immune response from the vaccine appears to be stronger than from natural infection, a moderate decrease in efficacy could still provide a meaningful degree of protection. In response to the concerning results, Moderna announced that it is in the process of developing a new booster that is tailored to provide increased protection against the B.1.351 variant. Additionally, Moderna is testing the effect of a second booster dose of the existing vaccine to determine any additional benefit in terms of protection against the B.1.351 variant. Considering that Moderna’s existing vaccine is already authorized for use in multiple countries, it is unclear what the regulatory review process would look like for a new booster or an additional booster dose.
AUSTRALIA VACCINE AUTHORIZATION On January 25, the Australian Therapeutic Goods Administration granted provisional authorization for the use of the Pfizer/BioNTech vaccine candidate. The provisional approval applies for use in individuals aged 16 years and older, and vaccinations are expected to begin in February. Australian Prime Minister Scott Morrison emphasized that the provisional approval is different from an emergency authorization and requires a more comprehensive review of the vaccine’s safety and efficacy, among the first such effort globally. The vaccine will be provided for free to all Australian citizens. According to the National Rollout Strategy, as many as 1.4 million doses will be distributed to “1a” priority groups, which include healthcare workers, long-term care facility staff and residents, and border and quarantine workers. The vaccine will initially be delivered to 50 priority vaccination sites during Phase 1a and then expanded to more than 1,000 sites nationwide. The initial vaccine hubs are concentrated in coastal areas, where the majority of the population resides. Few of the initial sites are located in Australia’s interior where many aboriginal communities reside. Australian authorities must set up cold storage facilities and train vaccinators in advance of beginning Phase 1a, and each batch will be tested before doses are administered.
VACCINE DONATIONS India has pledged to donate more than 4.5 million doses of the AstraZeneca vaccine, manufactured in India by the Serum Institute, to several neighboring countries. Deliveries have reportedly already arrived in Bangladesh, Bhutan, Maldives, Mauritius, Nepal, and Seychelles, and additional donations are expected for Afghanistan and Sri Lanka. India has already stockpiled 80 million doses of the AstraZeneca vaccine, and it is expected to manufacture an additional 50 million doses per month. In addition to India, China has donated vaccine to numerous countries, including Myanmar, Cambodia, Philippines, and Pakistan. Commentators have noted that these donations may be a strategic form of diplomacy that aims, in part, to increase political influence in the region and improve bilateral relations. In addition to donations, both India and China have also sold doses of vaccine to global partners.
US TRAVEL RESTRICTIONS Yesterday, US President Joe Biden issued travel restrictions for several countries that are currently experiencing increased COVID-19 incidence, including several emerging variants of SARS-CoV-2. The restrictions apply to individuals who traveled to Brazil, Ireland, South Africa, the UK, or any country in the EU (Schengen Area) in the 14 days prior to their arrival in the US. The restrictions existed previously for Brazil, Ireland, the UK, and the EU, but South Africa is new to the list. The presidential proclamation took effect today. Dr. Anthony Fauci described the restrictions as “very prudent,” particularly as new evidence indicates that these emerging variants may be associated with increased mortality risk. Exceptions to the new policy include US citizens, permanent residents, noncitizen nationals, certain immediate family members of permanent residents or citizens, individuals who fall under exceptions related to US national interests and individuals seeking asylum.
MEXICAN PRESIDENT On Sunday, Mexican President Andrés Manuel López Obrador announced that he tested positive for SARS-CoV-2. President Obrador described his symptoms as “mild,” but he is currently undergoing medical treatment. President Obrador will continue to isolate at home, and he has handed off responsibility for daily news conferences to Mexico’s Secretary of the Interior, Olga Sánchez Cordero. President Obrador had not yet been vaccinated against SARS-CoV-2.
RESTRICTIONS & PROTESTS For the past several days in the Netherlands, protests against stronger COVID-19 restrictions have turned violent. The Dutch government implemented new ”lockdown measures” on January 23, including a nighttime curfew from 8:30pm-4:30am, a travel advisory discouraging any travel out of the country, and a limit of 1 visitor per household per day. The curfew, in particular, drew opposition from the public. As we covered previously, the last time that the Netherlands implemented a nationwide curfew was during World War II. The large public protests turned violent on Sunday the 24, reportedly including a fire at a SARS-CoV-2 testing center. Since then, hundreds of protestors have been arrested, and several cities have imposed ordinances against entering the city center in order to suppress further riots. Prime Minister Mark Rutte condemned the riots, describing the events as instances of criminal violence rather than protests. The curfew and other new measures are scheduled to remain in place through February 9.
ECONOMIC IMPACT & RECOVERY A report published this week by Oxfam International illustrates significant disparities in terms of the financial impact of the COVID-19 pandemic. The report—released to coincide with the annual World Economic Forum summit typically held in Davos, Switzerland—indicates that the “mega-rich” have already recovered financially from the pandemic, whereas the world’s poorest could take years or longer. Notably, the research suggests that COVID-19 could exacerbate economic inequalities in nearly every country on Earth. The 1,000 wealthiest people in the world, “mostly White male,” took approximately 9 months to recuperate financial losses, but those living in poverty are expected to take more than a decade to recover. The analysis also estimates that “the increase in the 10 richest billionaires’ wealth since the crisis began [more than US$500 billion] is more than enough to prevent anyone on Earth from falling into poverty because of the virus, and to pay for a COVID-19 vaccine for everyone.” Notably, women and racial and ethnic minorities are disproportionately affected by the global economic crisis. In addition to shorter-term and immediate financial struggles, many people around the world will face prolonged financial hardship stemming from the pandemic, compounding economic inequalities around the world.
https://covid19.who.int/
Last edited by dryrunguy on Wed Jan 27, 2021 1:29 am, edited 1 time in total.
- ponchi101
- Site Admin
- Posts: 16460
- Joined: Mon Dec 07, 2020 4:40 pm
- Location: New Macondo
- Has thanked: 4173 times
- Been thanked: 6470 times
- Contact:
Re: Covid-19 Updates & Info
(ok, make sure you used the right buttons, you jerk...)dryrunguy wrote: ↑Wed Jan 27, 2021 12:50 am Here's the most recent Situation Report.
::
...
ECONOMIC IMPACT & RECOVERY A report published this week by Oxfam International illustrates significant disparities in terms of the financial impact of the COVID-19 pandemic. The report—released to coincide with the annual World Economic Forum summit typically held in Davos, Switzerland—indicates that the “mega-rich” have already recovered financially from the pandemic, whereas the world’s poorest could take years or longer. Notably, the research suggests that COVID-19 could exacerbate economic inequalities in nearly every country on Earth. The 1,000 wealthiest people in the world, “mostly White male,” took approximately 9 months to recuperate financial losses, but those living in poverty are expected to take more than a decade to recover. The analysis also estimates that “the increase in the 10 richest billionaires’ wealth since the crisis began [more than US$500 billion] is more than enough to prevent anyone on Earth from falling into poverty because of the virus, and to pay for a COVID-19 vaccine for everyone.” Notably, women and racial and ethnic minorities are disproportionately affected by the global economic crisis. In addition to shorter-term and immediate financial struggles, many people around the world will face prolonged financial hardship stemming from the pandemic, compounding economic inequalities around the world.
https://covid19.who.int/
Ok, seriously here. I am really trying to NOT be a jerk. Did you strike out that section so we would not be depressed? I mean, you failed, but I want to know if you did it for protection (us).
That has to be the second most terrible aspect of this pandemic.
Time for a world tax (I dream out loud)
Ego figere omnia et scio supellectilem
- dryrunguy
- Posts: 1622
- Joined: Thu Dec 10, 2020 6:31 am
- Has thanked: 724 times
- Been thanked: 1195 times
Re: Covid-19 Updates & Info
LOL! I haven't even read the report yet. But when you struck through that text in your post, it struck through the text in my original post. I should be able to fix it, but I don't want anyone thinking I did that. LOL!
- Deuce
- Posts: 4531
- Joined: Wed Dec 09, 2020 5:52 am
- Location: An unparallel universe
- Has thanked: 313 times
- Been thanked: 955 times
Re: Covid-19 Updates & Info
Sure, they're islands, but with air travel, that makes them as easily accessible as places like Canada and the U.S., as North America is quite different than Europe in terms of North American countries being larger and more independent of each other.
Here, the U.S./Canada land border has been closed since last March - but air travel between the countries has been allowed for some idiotic reason.
And therein lies the difference between how Australia has dealt with the virus and the manner in which most other countries have managed it. I think it has less to do with them being an island, and more to do with the way things have been managed.
R.I.P. Amal...
“The opposite of courage is not cowardice - it’s conformity. Even a dead fish can go with the flow.”- Jim Hightower
“The opposite of courage is not cowardice - it’s conformity. Even a dead fish can go with the flow.”- Jim Hightower
- Suliso
- Posts: 4771
- Joined: Fri Dec 11, 2020 2:30 pm
- Location: Basel, Switzerland
- Has thanked: 291 times
- Been thanked: 1608 times
Re: Covid-19 Updates & Info
Did you also consider thousands of lorries crossing the Canada/US border every day delivering food, factory spare parts etc? In Detroit area, for example, auto manufacturing on US side is highly integrated with just in time parts production on Canadian side. And then there is a road traffic to Alaska too. No such complications in Australia or NZ.Deuce wrote: ↑Wed Jan 27, 2021 2:52 amSure, they're islands, but with air travel, that makes them as easily accessible as places like Canada and the U.S., as North America is quite different than Europe in terms of North American countries being larger and more independent of each other.
Here, the U.S./Canada land border has been closed since last March - but air travel between the countries has been allowed for some idiotic reason.
And therein lies the difference between how Australia has dealt with the virus and the manner in which most other countries have managed it. I think it has less to do with them being an island, and more to do with the way things have been managed.
- atlpam
- Posts: 445
- Joined: Thu Dec 10, 2020 5:32 pm
- Location: GA
- Has thanked: 32 times
- Been thanked: 267 times
Re: Covid-19 Updates & Info
My husband is scheduled for his 1st dose tomorrow. I think it will be at least May before I am eligible (phase 2). My son is in phase 1B (critical workforce - he's an Air Traffic Controller), but no word yet on when his group will be eligible (maybe March?) The scheduling is very hit or miss here in GA as you never really know when they will open up appts and every provider has a different scheduling process.
- ponchi101
- Site Admin
- Posts: 16460
- Joined: Mon Dec 07, 2020 4:40 pm
- Location: New Macondo
- Has thanked: 4173 times
- Been thanked: 6470 times
- Contact:
Re: Covid-19 Updates & Info
My theory is this. They are islands that did lock down very fast, and could do so. Other countries that have been successful have been Singapore (another island) and S. Korea, which is technically an island as their border with N. Korea is locked down. They also are affluent nations with large social security networks. What I said above: their population could afford a lock down and not have to worry about going hungry, which is what here in Colombia cannot be done.Deuce wrote: ↑Wed Jan 27, 2021 2:52 am
Sure, they're islands, but with air travel, that makes them as easily accessible as places like Canada and the U.S., as North America is quite different than Europe in terms of North American countries being larger and more independent of each other.
Here, the U.S./Canada land border has been closed since last March - but air travel between the countries has been allowed for some idiotic reason.
And therein lies the difference between how Australia has dealt with the virus and the manner in which most other countries have managed it. I think it has less to do with them being an island, and more to do with the way things have been managed.
Sure, they had proper a proper response, but that has been my gripe for quite a while. The income disparity between countries, which is reflected in that last terrible paragraph in Dry's report, makes it impossible for hundred of millions of people to really stop working. Bogota simply cannot remain locked down, as the small businesses (and Bogota is nothing more than small businesses) cannot afford more than one month or two of lock down. Their workers even less.
Ego figere omnia et scio supellectilem
- ponchi101
- Site Admin
- Posts: 16460
- Joined: Mon Dec 07, 2020 4:40 pm
- Location: New Macondo
- Has thanked: 4173 times
- Been thanked: 6470 times
- Contact:
Re: Covid-19 Updates & Info
BTW:
After one year of this, it seems that the Sweden experiment did not go well at all. Their death rate is huge in comparison to their three Scandinavian neighbors.
After one year of this, it seems that the Sweden experiment did not go well at all. Their death rate is huge in comparison to their three Scandinavian neighbors.
Ego figere omnia et scio supellectilem
Who is online
Users browsing this forum: No registered users and 1 guest